Quantifying the Natural Growth Rate of Hepatocellular Carcinoma: A Real-world Retrospective Study in Southwestern China

Overview

Journal World J Hepatol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2024 May 31

PMID 38818290

Authors

Li Tu

Hong Xie

Qi Li

Ping-Gui Lei

Pei-Ling Zhao

Fan Yang

Chi Gong

Yuan-Lin Yao

Shi Zhou

Affiliations

Soon will be listed here.

Abstract

Background: In recent years, approximately half of the newly diagnosed cases and mortalities attributed to hepatocellular carcinoma (HCC) have been reported in China. Despite the high incidence of HCC, there remains a paucity of data regarding the natural growth pattern and the determination of optimal surveillance intervals specific to the Chinese population.

Aim: To quantify the natural tumor growth pattern of HCC in regional China.

Methods: A retrospective analysis was performed on patients from a single institution in Southwest China who had undergone two or more serial dynamic computed tomography or magnetic resonance imaging scans between 2014 and 2020, without having received any anti-cancer therapy. Tumor growth was assessed using tumor volume doubling time (TVDT) and tumor growth rate (TGR), with volumes measured manually by experienced radiologists. Simple univariate linear regression and descriptive analysis were applied to explore associations between growth rates and clinical factors.

Results: This study identifies the median TVDT for HCC as 163.4 d, interquartile range (IQR) 72.1 to 302.3 d, with a daily TGR of 0.42% (IQR 0.206%-0.97%). HCC growth patterns reveal that about one-third of tumors grow indolently with TVDT exceeding 270 d, another one-third of tumors exhibit rapid growth with TVDT under 90 d, and the remaining tumors show intermediate growth rates, with TVDT ranging between 3 to 9 months.

Conclusion: The identified TGRs support biannual surveillance and follow-up for HCC patients in certain regions of China. Given the observed heterogeneity in HCC growth, further investigation is warranted.

References

Qi J, Li M, Wang L, Hu Y, Liu W, Long Z . National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data. Lancet Public Health. 2023; 8(12):e943-e955. DOI: 10.1016/S2468-2667(23)00211-6. View

Chernyak V, Fowler K, Kamaya A, Kielar A, Elsayes K, Bashir M . Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology. 2018; 289(3):816-830. PMC: 6677371. DOI: 10.1148/radiol.2018181494. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Nathani P, Gopal P, Rich N, Yopp A, Yokoo T, John B . Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis. Gut. 2020; 70(2):401-407. PMC: 7657990. DOI: 10.1136/gutjnl-2020-321040. View

Kamath A, Roudenko A, Hecht E, Sirlin C, Chernyak V, Fowler K . CT/MR LI-RADS 2018: clinical implications and management recommendations. Abdom Radiol (NY). 2019; 44(4):1306-1322. DOI: 10.1007/s00261-018-1868-6. View

Schwartz M . A biomathematical approach to clinical tumor growth. Cancer. 1961; 14:1272-94. DOI: 10.1002/1097-0142(196111/12)14:6<1272::aid-cncr2820140618>3.0.co;2-h. View

Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag C, Vignat J . Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022; 77(6):1598-1606. PMC: 9670241. DOI: 10.1016/j.jhep.2022.08.021. View

Valery P, Laversanne M, Clark P, Petrick J, McGlynn K, Bray F . Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology. 2017; 67(2):600-611. PMC: 5832532. DOI: 10.1002/hep.29498. View

Rich N, John B, Parikh N, Rowe I, Mehta N, Khatri G . Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis. Hepatology. 2020; 72(5):1654-1665. PMC: 7398837. DOI: 10.1002/hep.31159. View

10.

Zheng R, Qu C, Zhang S, Zeng H, Sun K, Gu X . Liver cancer incidence and mortality in China: Temporal trends and projections to 2030. Chin J Cancer Res. 2019; 30(6):571-579. PMC: 6328503. DOI: 10.21147/j.issn.1000-9604.2018.06.01. View

11.

Rebouissou S, Nault J . Advances in molecular classification and precision oncology in hepatocellular carcinoma. J Hepatol. 2020; 72(2):215-229. DOI: 10.1016/j.jhep.2019.08.017. View

12.

Ebara M, OHTO M, Shinagawa T, Sugiura N, Kimura K, Matsutani S . Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients. Gastroenterology. 1986; 90(2):289-98. DOI: 10.1016/0016-5085(86)90923-6. View

13.

Matsuhashi T, Yamada N, Shinzawa H, Takahashi T . Effect of alcohol on tumor growth of hepatocellular carcinoma with type C cirrhosis. Intern Med. 1996; 35(6):443-8. DOI: 10.2169/internalmedicine.35.443. View

14.

Okazaki N, Yoshino M, Yoshida T, Suzuki M, Moriyama N, Takayasu K . Evaluation of the prognosis for small hepatocellular carcinoma based on tumor volume doubling time. A preliminary report. Cancer. 1989; 63(11):2207-10. DOI: 10.1002/1097-0142(19890601)63:11<2207::aid-cncr2820631124>3.0.co;2-c. View

15.

Furlan A, Marin D, Agnello F, Di Martino M, Di Marco V, Lagalla R . Hepatocellular carcinoma presenting at contrast-enhanced multi-detector-row computed tomography or gadolinium-enhanced magnetic resonance imaging as a small (≤2 cm), indeterminate nodule: growth rate and optimal interval time for imaging follow-up. J Comput Assist Tomogr. 2012; 36(1):20-5. DOI: 10.1097/RCT.0b013e31823ed462. View

16.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

17.

But D, Lai C, Yuen M . Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol. 2008; 14(11):1652-6. PMC: 2695904. DOI: 10.3748/wjg.14.1652. View

18.

Marks R, Masch W, Chernyak V . LI-RADS: Past, Present, and Future, From the Special Series on Radiology Reporting and Data Systems. AJR Am J Roentgenol. 2020; 216(2):295-304. DOI: 10.2214/AJR.20.24272. View

19.

Sheu J, SUNG J, Chen D, Yang P, Lai M, Lee C . Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology. 1985; 89(2):259-66. DOI: 10.1016/0016-5085(85)90324-5. View

20.

Villanueva A . Hepatocellular Carcinoma. N Engl J Med. 2019; 380(15):1450-1462. DOI: 10.1056/NEJMra1713263. View